达安基因(002030.SZ)：广药集团拟成为公司间接控股股东

Core Viewpoint - Da An Gene (002030.SZ) has received notifications from Guangzhou Financial Holdings Group, Guangzhou Health Industry Investment, and Guangzhou Pharmaceutical Group regarding a framework agreement signed on November 15, 2025, for the transfer of shares [1][2] Group 1 - Guangzhou Financial Holdings Group plans to transfer its 100% stake in Guangyong Technology, which includes a 16.63% stake in Da An Gene, along with a 5% stake held by itself and another 5% stake held by Guangzhou Health Industry Investment to Guangzhou Pharmaceutical Group or its designated affiliates [1] - The total consideration for this transaction will be the sum of the transfer price for the equity and the consideration specified in the agreement [1] Group 2 - Before the equity change, Guangzhou Financial Holdings Group was the indirect controlling shareholder of Da An Gene, holding a total of 443,908,904 shares, representing a 31.63% stake [2] - If the equity change is completed, Guangzhou Pharmaceutical Group will become the indirect controlling shareholder, controlling 373,736,601 shares, which is 26.63% of the total share capital, while Guangzhou Financial Holdings Group will retain a 5% stake through Guangzhou Health Industry Investment [2] - The controlling shareholder will remain Guangyong Technology, and the actual controller will still be the Guangzhou Municipal Government, indicating no change in control [2]